Compare Nuwellis Inc (NUWE) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs DENTSPLY SIRONA Inc — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while DENTSPLY SIRONA Inc trades at $8.67 (market cap $1.70B). The key difference: DENTSPLY SIRONA Inc is far larger — about 772.7× Nuwellis Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| NUWE | XRAY | |
|---|---|---|
Market Cap | $2.20M | $1.70B |
Volume | 121,544 | 4,220,050 |
Sector | Health | Health |
52-Week High | $146.65 | $14.68 |
52-Week Low | $0.68 | $8.52 |
Typical Hold Time | 26 Days | 72 Days |
Enterprise Value | -$1.52M | $3.78B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
DENTSPLY SIRONA (XRAY) trades at $8.69, near its 52-week low, with bearish technical signals and declining revenue trends. The company reported Q2 2026 earnings beat but faces margin pressure and negative profitability metrics. Recent news highlights institutional stake increases and ongoing restructuring efforts amid challenging dental market conditions.
The stock presents a high-risk opportunity with analyst consensus target of $13.40 suggesting 54% upside potential. However, persistent net losses, declining revenue, and bearish technical indicators warrant caution. Recovery depends on successful execution of turnaround initiatives and market share stabilization in competitive dental equipment sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
